84 research outputs found
Measuring oxytocin and vasopressin:bioassays, immunoassays and random numbers
In this review, we consider the ways in which vasopressin and oxytocin have been measured since their first discovery. Two different ways of measuring oxytocin in widespread use currently give values in human plasma that differ by two orders of magnitude, and the values measured by these two methods in the same samples show no correlation. The notion that we should accept this seems absurd. Either one (or both) methods is not measuring oxytocin, or, by ‘oxytocin’, the scientists that use these different methods mean something very different. If these communities are to talk to each other, it is important to validate one method and invalidate the other, or else to establish exactly what each community understands by ‘oxytocin’. A similar issue concerns vasopressin: again, different ways of measuring vasopressin give values in human plasma that differ by two orders of magnitude, and it appears that the same explanation for discrepant oxytocin measurements applies to discrepant vasopressin measurements. The first assays for oxytocin and vasopressin measured biological activity directly. When immunoassays were introduced, they encountered problems: high molecular weight factors in raw plasma interfered with the binding of antibodies to the hormones, leading to high and erroneous readings. When these interfering factors were removed by extraction of plasma samples, immunoassays gave measurements consistent with bioassays, with measures of turnover and with the sensitivity of target tissues to exogenous hormone. However, many recent papers use an enzyme‐linked immunoassay to measure plasma levels without extracting the samples. Like the first radioimmunassays of unextracted plasma, this generates impossibly high and wholly erroneous measurements
Performative Kämpfe der Migration. Eine ethnographische Grenzregimeanalyse der Widerstände gegen die Lagerpolitik im Kanton Zürich
Hypotensive effect of guanfacine in essential hypertension: a comparison with clonidine.
Preliminary investigations of a new beta-adrenoceptive receptor blocking drug, LB46, in man
THE ACTION OF THE SYNTHETIC POLYPEPTIDE VALYL-OXYTOCIN ON THE HUMAN UTERUS IN VITRO AND IN VIVO
CLINICAL DOSE-RESPONSE STUDIES WITH GUANFACINE (BS 100-141), A NEW ANTIHYPERTENSIVE AGENT
- …